The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Open accessAbstract
Functional cure of hepatitis B is defined as sustained undetectable circulating HBsAg and HBV DNA after a finite course of treatment. Barriers to HBV cure include the reservoirs for HBV replication and antigen production (covalently closed circular DNA [cccDNA] and integrated HBV DNA), the high viral burden (HBV DNA and HBsAg) and the impaired host innate and adaptive immune responses against HBV. Current HBV therapeutics, 1 year of pegylated-interferon-α (PEG-IFNα) and long-term nucleos(t)ide analogues (NUCs), rarely achieve HBV cure. Stopping NUC therapy may lead to functional cure in some Caucasian patients but rarely in Asian patients. Switching from a NUC to IFN after HBV DNA suppression increases the chance of HBsAg clearance mainly in those with low HBsAg levels. Novel antiviral strategies that inhibit viral entry, translation and secretion of HBsAg, modulate capsid assembly, or target cccDNA transcription/degradation have shown promise in clinical trials. Novel immunomodulatory approaches including checkpoint inhibitors, metabolic modulation of T cells, therapeutic vaccines, adoptive transfer of genetically engineered T cells, and stimulation of innate and B-cell immune responses are being explored. These novel approaches may be further combined with NUCs or PEG-IFNα in personalised strategies, according to virologic and disease characteristics, to maximise the chance of HBV cure. The development of curative HBV therapies should be coupled with the development of standardised and validated virologic and immunologic assays to confirm target engagement and to assess response. In addition to efficacy, curative therapies must be safe and affordable to meet the goal of global elimination of hepatitis B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61412-x · Cited by 2,742
Razavi-Shearer, D., Gamkrelidze, I., Nguyen, M. H., Chen, D.-S., Van Damme, P., Abbas, Z., Abdulla, M., Abou Rached, A., Adda, D., Aho, I., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30056-6 · Cited by 1,661
Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA
Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., Sprinzl, M. F., Koppensteiner, H., Makowska, Z., Volz, T., et al. (2014) · Science · doi:10.1126/science.1243462 · Cited by 893
Rehermann, B., Ferrari, C., Pasquinelli, C., & Chisari, F. V. (1996) · Nature Medicine · doi:10.1038/nm1096-1104 · Cited by 854
Wooddell, C. I., Yuen, M.-F., Chan, H. L.-Y., Gish, R. G., Locarnini, S. A., Chavez, D., Ferrari, C., Given, B. D., Hamilton, J., Kanner, S. B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0241 · Cited by 490
Adaptive immunity in HBV infection
Bertoletti, A., & Ferrari, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.026 · Cited by 483
Lanford, R. E., Guerra, B., Chavez, D., Giavedoni, L., Hodara, V. L., Brasky, K. M., Fosdick, A., Frey, C. R., Zheng, J., Wolfgang, G., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.003 · Cited by 377
Boni, C., Laccabue, D., Lampertico, P., Giuberti, T., Viganò, M., Schivazappa, S., Alfieri, A., Pesci, M., Gaeta, G. B., Brancaccio, G., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.014 · Cited by 377
The role of quantitative hepatitis B surface antigen revisited
Cornberg, M., Wong, V. W.-S., Locarnini, S., Brunetto, M., Janssen, H. L. A., & Chan, H. L.-Y. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.009 · Cited by 372
Cornberg, M., Lok, A. S.-F., Terrault, N. A., Zoulim, F., Berg, T., Brunetto, M. R., Buchholz, S., Buti, M., Chan, H. L. Y., Chang, K.-M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.003 · Cited by 366
Self-citation
Cited by
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Ma, X., Huang, T., Chen, X., Li, Q., Liao, M., Fu, L., Huang, J., Yuan, K., Wang, Z., & Zeng, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02104-8 · Cited by 133
Metadata
- Authors
- Wong, G. L. H., Gane, E., & Lok, A. S. F.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 76
- Issue
- 6
- Pages
- 1249-1262
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W4280582189
- Cited by
- 272
- References
- 46
- FWCI
- 33.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? https://app.cochat.ai/papers/10.1016/j.jhep.2021.11.024
- The paper
- Wong, G. L. H., Gane, E., & Lok, A. S. F. (2022). How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? Journal of Hepatology. https://doi.org/10.1016/j.jhep.2021.11.024
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.